APG Stock Recent News

While the top- and bottom-line numbers for APi (APG) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

APi (APG) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.34 per share a year ago.

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today reported its financial results for the three months ended March 31, 2025. Russ Becker, APi's President and Chief Executive Officer stated: “We are off to a strong start in 2025, with a return to traditional levels of organic growth after our thoughtful and selective pruning of certain customer accounts in 2024. We've also continued to expand margins and deploy capital on M&A and share repu.

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) announced today that it intends to release its financial results for the three months ended March 31, 2025, before the market opens on Thursday, May 1, 2025. First Quarter Earnings Conference Call APi will hold a webcast/dial-in conference call to discuss its financial results at 8:30 a.m. (Eastern Time) on Thursday, May 1, 2025. Participants on the call will include Russell A. Becker, President and.

Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious pipeline development in inflammatory diseases. Significant R&D investments in lead IL-13 inhibitor APG777 and combination therapies reflect a strategic push for differentiated, best-in-class treatments in atopic dermatitis and asthma. Encouraging Phase 1 data for OX40L inhibitor APG990 supports its combination potential with APG777, promising infrequent dosing and broad efficacy in inflammatory diseases.

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced the appointment of David Jackola as Executive Vice President & Chief Financial Officer, effective immediately. Mr. Jackola has been with the Company since October 2021, most recently serving as Interim Chief Financial Officer since December of 2024. He will report directly to Russ Becker, President and Chief Executive Officer of APi. Russ Becker, APi's President and Chief Executi.

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi”) today announced that its senior leadership will be participating in a fireside chat during the 2025 J.P. Morgan Industrials Conference on Wednesday, March 12th at 10:30 a.m. ET. A live webcast link and archived replay will be available in the “Events” area on the Investor Relations page of APi's website at www.apigroupcorp.com. Interested parties should check the Company's website for any schedule updates or time ch.

I am downgrading APi Group (APG) to hold due to uncertain near-term performance, weak organic growth, and macro uncertainties impacting FY25 outlook. Despite solid 4Q24 adj EBITDA growth and a healthy backlog, APG's organic growth remains weak, particularly in the Specialty Services segment. APG's transition to high-margin ISM revenue is positive, but near-term organic growth concerns and potential macro risks could pressure the stock.

Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life

SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report interim results from the Phase 1 APG990 healthy volunteer trial on Monday, March 3, 2025. Following the announcement, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for its combination approach for APG777 + APG990.